title: Intellectual property issues of immune checkpoint inhibitors.
abstract: Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.
authors.affiliation: a Senior Partner, Michalski; Hüttermann Patent Attorneys ; Düsseldorf , Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Storz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D059447:Cell Cycle Checkpoints; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D010330:Patents as Topic
chemical_list: D000970:Antineoplastic Agents
keywords: CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; PD-L1; PD1; Yervoy; antibody; patent